Investment Theme
Therapeutics
Small molecules, biologics, and advanced therapy medicinal products (ATMPs) targeting diseases with high unmet medical need.
The Space
Therapeutics is the most capital-intensive and longest-horizon category ChaosBio reviews, and also the one where a pharmaceutical R&D background does the most work: reading a preclinical package, a development plan, or an IND-enabling strategy the way someone who has run one reads it, not the way a generalist investor reads a pitch deck.
The bar for a seed-stage therapeutics company is not "does the mechanism sound plausible." It is whether the evidence generated so far actually reduces the risk that matters most at this stage, and whether the plan to reach the next value-inflection point is realistic on the money being raised.
Why It Matters
The gap between promising and investable.
A real scientific advance can still fail to become a fundable company if the development plan does not sequence risk correctly, or if the team cannot get in front of the questions a later-stage investor or a pharma partner will ask.
Therapeutics diligence rewards someone who has actually built these plans before, not only reviewed them from the outside. That is the specific advantage a pharmaceutical R&D operator brings to a first meeting with a therapeutics founder.
The ChaosBio Lens
What ChaosBio looks for.
Applied to every therapeutics opportunity ChaosBio reviews, alongside the general investment framework.
Mechanism and evidence
Is the biology characterized rather than assumed, and does the data shown actually support the claim being made about it?
Development candidate strategy
Has the company nominated (or planned toward) a development candidate in a way that retires the most decisive risk first?
Regulatory and translational path
Is there a credible route through IND-enabling studies to a clinical or partnering milestone that investors and acquirers would recognize as real progress?
Capital efficiency
Does the amount being raised actually reach the next milestone that changes the value of the company, with room for the plan to slip?
Portfolio
Companies ChaosBio has backed in this space.
Related Reading
From the Journal.
See therapeutics opportunities as they come in.
Join the Investor Network for curated therapeutics and other early-stage life sciences opportunities, reviewed through the ChaosBio investment framework. Free, and no obligation to invest.